Tilray Brands Inc is a global leader in the cannabis industry, specializing in the cultivation, production, and distribution of a diverse range of cannabis products. The company operates across various segments, including medical and recreational cannabis, as well as hemp-derived wellness products. Tilray focuses on innovation and quality, offering a portfolio that encompasses various formats such as dried flower, oils, edibles, and beverages. In addition to its core cannabis business, Tilray is dedicated to advancing research, education, and consumer awareness within the rapidly evolving market, positioning itself as a key player in the development and expansion of cannabis-related offerings worldwide. Read More
NEUMÜNSTER, Germany, May 22, 2025 (GLOBE NEWSWIRE) -- Tilray Medical (“Tilray”), a division of Tilray Brands, Inc. (NASDAQ: TLRY and TSX: TLRY) and a global leader in medicinal cannabis, empowering the therapeutic alliance between patients and healthcare practitioners to make informed individualized health decisions, transforming healthcare, is pleased to announce the launch of Good Supply in Germany. Known for its consistent quality and affordability, Good Supply is one of Canada's leading cannabis brands and is recognized as a leading cannabis whole flower with its range of cultivars. The introduction of Good Supply in Germany aims to address the evolving medical cannabis landscape, providing patients with an affordable and reliable brand option for their medical cannabis needs.
Stocks under $10 pique our interest because they have room to grow (as well as the most affordable option contract premiums).
That doesn’t mean they’re bargains though, and we urge investors to be careful as many have risky business models.
Germany's cannabis access surges with 2,500 pharmacies and 211 grow clubs, but bans on edibles and retail sales still limit the market's full potential.
Consumer staples stocks are solid insurance policies in frothy markets ripe for corrections. But recently, the industry has failed to do its job as it shed 14% over the past six months. This drawdown was worse than the S&P 500’s 6.2% fall.
